 randomized placebo-controlled trial intravenous captopril recombinant tissue-type plasminogen activator therapy acute myocardial infarction adjunctive use intravenous captopril tissue plasminogen activator early acute myocardial infarction offers theoretic advantages left ventricular volume ventricular dilation patient survival safety efficacy early administration intravenous captopril recombinant tissue-type plasminogen activator rt-PA patients rt-PA mean SE onset myocardial infarction intravenous oral captopril placebo therapy underwent cardiac catheterization measurement hemodynamic variables ventricular function determination serum renin angiotensin aldosterone levels days Oral administration agent months antianginal medications nonangiotensin-converting enzyme inhibitor vasodilators Repeat measurements left ventricular function hospital discharge months significant differences baseline clinical characteristics groups patient captopril-treated group hypotensive intravenous therapy discontinuation treatment placebo-treated group captopril-treated group significant reductions day left ventricular end-diastolic pressure versus mm Hg mean systemic arterial pressure versus mm Hg